Acadia Pharmaceuticals ACAD Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's other income (expense)?
- Acadia Pharmaceuticals (ACAD) reported other income (expense) of $542K in Q1 2026.
- How has Acadia Pharmaceuticals's other income (expense) changed year-over-year?
- Acadia Pharmaceuticals's other income (expense) decreased by 7.8% year-over-year, from $588K to $542K.
- What is the long-term trend for Acadia Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's other income (expense) has grown at a 3.8% compound annual growth rate (CAGR), from $2.04M to $2.37M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.